5,130
Views
83
CrossRef citations to date
0
Altmetric
Research Article

Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks

, , ORCID Icon, , &
Pages 932-941 | Received 29 Mar 2017, Accepted 30 May 2017, Published online: 15 Jun 2017

References

  • Aditya NP, Macedo AS, Doktorovova S, et al. (2014). Development and evaluation of lipid nanocarriers for quercetin delivery: a comparative study of solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and lipid nanoemulsions (LNE). Food Sci Technol 59:115–21.
  • Ahmed IS, El-Hosary R, Shalaby S, et al. (2016). PD-PK evaluation of freeze-dried atorvastatin calcium-loaded poly-epsilon-caprolactone nanoparticles. Int J Pharm 504:70–9.
  • Anwar M, Warsi MH, Mallick N, et al. (2011). Enhanced bioavailability of nano-sized chitosan-atorvastatin conjugate after oral administration to rats. Eur J Pharm Sci 44:241–9.
  • Batrakova EV, Li S, Li Y, et al. (2004). Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm Res 21:2226–33.
  • Cavalli R, Bargoni A, Podio V, et al. (2003). Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci 92:1085–94.
  • Charman WN. (2000). Lipids, lipophilic drugs, and oral drug delivery – some emerging concepts. J Pharm Sci 89:967–78.
  • Chen CC, Tsai TH, Huang ZR, et al. (2010). Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm 74:474–82.
  • Chen TY, Pan BS. (2007). Ex vivo inhibitory effect on tilapia LDL oxidation and hypolipidemia properties of Glycine tomentella root extract. Comp Biochem Physiol A Mol Integr Physiol 148:189–95.
  • Choudhary A, Rana AC, Aggarwal G, et al. (2012). Development and characterization of an atorvastatin solid dispersion formulation using skimmed milk for improved oral bioavailability. Acta Pharmaceutica Sinica B 2:421–8.
  • Elbahwy IA, Ibrahim HM, Ismael HR, et al. (2017). Enhancing bioavailability and controlling the release of glibenclamide from optimized solid lipid nanoparticles. J Drug Deliv Sci Technol 38:78–89.
  • Elmowafy M, Samy A, Raslan MA, et al. (2016). Enhancement of bioavailability and pharmacodynamic effects of thymoquinone via nanostructured lipid carrier (NLC) formulation. AAPS PharmSciTech 17:663–72.
  • Guinedi AS, Mortada ND, Mansour S, et al. (2005). Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm 306:71–82.
  • He C, Yin L, Tang C, et al. (2012). Size-dependent absorption mechanism of polymeric nanoparticles for oral delivery of protein drugs. Biomaterials 33:8569–78.
  • Higuchi T. (1963). Mechanism of sustained‐action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 52:1145–9.
  • Hörter D, Dressman JB. (2001). Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev 46:75–87.
  • Hussein AK, Ibrahim MA, Amin MA, et al. (2011). Improved in vitro dissolution parameters and in vivo hypolipidemic efficiency of atorvastatin calcium through the formation of hydrophilic inclusion complex with cyclodextrins. Drug Dev Res 72:379--90.
  • Hyogo H, Yamagishi S, Maeda S, et al. (2012). Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-alpha-lowering property. Dig Liver Dis 44:492–6.
  • Jeong W-I, Jeong D-H, Do S-H, et al. (2005). Mild hepatic fibrosis in cholesterol and sodium cholate diet-fed rats. J Vet Med Sci 67:235–42.
  • Jia LJ, Zhang DR, Li ZY, et al. (2010). Preparation and characterization of silybin-loaded nanostructured lipid carriers. Drug Deliv 17:11–18.
  • Joshi M, Patravale V. (2008). Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm 346:124–32.
  • Kim MS, Jin SJ, Kim JS, et al. (2008). Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm 69:454–65.
  • Kleiner DE, Brunt EM, Van Natta M, et al.; Nonalcoholic Steatohepatitis Clinical Research, N. (2005). Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41:1313–21.
  • Lau YY, Okochi H, Huang Y, et al. (2006). Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos 34:1175–81.
  • Levy M, Benita S. (1990). Drug release from submicronized o/w emulsion: a new in vitro kinetic evaluation model. Int J Pharm 66:29–37.
  • Marasini N, Yan YD, Poudel BK, et al. (2012). Development and optimization of self-nanoemulsifying drug delivery system with enhanced bioavailability by Box-Behnken design and desirability function. J Pharm Sci 101:4584–96.
  • Muller RH, Petersen RD, Hommoss A, et al. (2007). Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 59:522–30.
  • Müller RH, Rühl D, Runge SA. (1996). Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int J Pharm 144:115–21.
  • O'driscoll CM, Griffin BT. (2008). Biopharmaceutical challenges associated with drugs with low aqueous solubility–the potential impact of lipid-based formulations. Adv Drug Deliv Rev 60:617–24.
  • Porter C. (2001). Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev 50:61–80.
  • Ravi PR, Aditya N, Kathuria H, et al. (2014). Lipid nanoparticles for oral delivery of raloxifene: optimization, stability, in vivo evaluation and uptake mechanism. Eur J Pharm Biopharm 87:114–24.
  • Sachs-Barrable K, Thamboo A, Lee SD, et al. (2007). Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of Rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 Cells. J Pharm Pharm Sci 10:319–31.
  • Sanad RA, Abdelmalak NS, Elbayoomy TS, et al. (2010). Formulation of a novel oxybenzone-loaded nanostructured lipid carriers (NLCs). AAPS PharmSciTech 11:1684–94.
  • Saupe A, Wissing SA, Lenk A, et al. (2005). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) – structural investigations on two different carrier systems. Biomed Mater Eng 15:393–402.
  • Shah RP, Kumar V, Singh S. (2008). Liquid chromatography/mass spectrometric studies on atorvastatin and its stress degradation products. Rapid Commun Mass Spectrom 22:613–22.
  • Shete H, Patravale V. (2013). Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization. Int J Pharm 454:573–83.
  • Souto EB, Wissing SA, Barbosa CM, et al. (2004). Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 278:71–7.
  • Tiwari R, Pathak K. (2011). Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm 415:232–43.
  • Vila L, Rebollo A, Adalsteisson GS, et al. (2011). Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. Toxicol Appl Pharmacol 251:32–40.
  • Vila L, Roglans N, Alegret M, et al. (2008). Suppressor of cytokine signaling-3 (SOCS-3) and a deficit of serine/threonine (Ser/Thr) phosphoproteins involved in leptin transduction mediate the effect of fructose on rat liver lipid metabolism. Hepatology 48:1506–16.
  • Wang J, Xia Q. (2014). Alpha-lipoic acid-loaded nanostructured lipid carrier: sustained release and biocompatibility to HaCaT cells in vitro. Drug Deliv 21:328–41.
  • Wong PCH, Heng PWS, Chan LW. (2016). Viscosity-temperature relationship of lipid-based excipients amenable for spray congealing: derivation of a rheological parameter with good correlation to particle size. Eur J Lipid Sci Technol 118:1062–73.
  • Xu X, Khan MA, Burgess DJ. (2012). A two-stage reverse dialysis in vitro dissolution testing method for passive targeted liposomes. Int J Pharm 426:211–18.
  • Yu Q, Hu X, Ma Y, et al. (2016). Lipids-based nanostructured lipid carriers (NLCs) for improved oral bioavailability of sirolimus. Drug Deliv 23:1469–75.
  • Zhang L, Han L, Sun X, et al. (2012). The use of PEGylated liposomes to prolong the circulation lifetime of salvianolic acid B. Fitoterapia 83:678–89.
  • Zheng S, Hoos L, Cook J, et al. (2008). Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol 584:118–24.
  • Zhuang CY, Li N, Wang M, et al. (2010). Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm 394:179–85.